Difference between revisions of "Part:BBa K2440004"
 
(One intermediate revision by the same user not shown)
Line 8: Line 8:
  
 
Argonaute 2 gene belongs to the argonaute gene family, which encodes for four characteristic domains: N- terminal, PAZ, Mid and a C-terminal PIWI domain. <sup>2 </sup>
 
Argonaute 2 gene belongs to the argonaute gene family, which encodes for four characteristic domains: N- terminal, PAZ, Mid and a C-terminal PIWI domain. <sup>2 </sup>
 +
 
The PAZ domain is named after proteins PIWI, AGO, and Zwille. It binding with the 3' end of siRNA and miRNA due to recognizes the sequence independent manner. The miRNA binds to mRNAs in the partially-complementary sites and reduces its stability and expression levels. <sup>3 </sup>
 
The PAZ domain is named after proteins PIWI, AGO, and Zwille. It binding with the 3' end of siRNA and miRNA due to recognizes the sequence independent manner. The miRNA binds to mRNAs in the partially-complementary sites and reduces its stability and expression levels. <sup>3 </sup>
 +
 
The C-terminal PIWI domain is named after Drosophila PIWI protein. It participates in the cleavage activity of his target. <sup>4 </sup>
 
The C-terminal PIWI domain is named after Drosophila PIWI protein. It participates in the cleavage activity of his target. <sup>4 </sup>
−
Argonaute proteins associate with small RNAs that guide mRNA degradation, translational repression, or a combination of both. The high sequence specificity of Argonaute 2 gene in RNA interference phenomenon in the protein may make it become a suitable treatment for the diseases with elevated expression level of specific gene such as pancreatic cancer. <sup>5 </sup>  
+
 
 +
Argonaute proteins associate with small RNAs that guide mRNA degradation, translational repression, or a combination of both. The high sequence specificity of Argonaute 2 gene in RNA interference phenomenon in the protein may make it become a suitable treatment for the diseases with elevated expression level of specific gene such as pancreatic cancer. <sup>5 </sup>
  
 
===Sequence and Features===
 
===Sequence and Features===
Line 22: Line 25:
 
<partinfo>BBa_K2440004 parameters</partinfo>
 
<partinfo>BBa_K2440004 parameters</partinfo>
 
<!-- -->
 
<!-- -->
 +
 +
===Reference===
 +
 +
[1] Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, Tuschl T.(2004 Jul). "Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs". Mol Cell. 23;15(2):185-97. PMID: 15260970 DOI: 10.1016/j.molcel.2004.07.007
 +
 +
[2] Hutvagner G, Simard MJ. (2008). "Argonaute proteins: key players in RNA silencing". Nature Reviews Molecular Cell Biology. 9 (1): 22–32. DOI: 10.1038/nrm2321
 +
 +
[3] Tang G. (Feb 2005). "siRNA and miRNA: an insight into RISCs.". Trends in Biochemical Sciences. 30 (2): 106–14. PMID 15691656. DOI: 10.1016/j.tibs.2004.12.007.
 +
 +
[4] Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, Tuschl T. (Jul 2004). "Human Argonaute2 Mediates RNA Cleavage Targeted by miRNAs and siRNAs". Molecular Cell. 15 (2): 185–197. PMID 15260970. DOI: 10.1016/j.molcel.2004.07.007.
 +
 +
[5] Ronemus M, Vaughn MW, Martienssen RA. (2006 Jul). "MicroRNA-targeted and small interfering RNA-mediated mRNA degradation is regulated by argonaute, dicer, and RNA-dependent RNA polymerase in Arabidopsis".  Plant Cell. 18(7):1559-74. Epub 2006 Jun 23. PMID: 16798886 PMCID: PMC1488920 DOI: 10.1105/tpc.106.042127

Latest revision as of 12:39, 30 October 2017


hAgo2

This is a human gene encoding the argonaute 2 protein. It can be used for RNA silencing research through RNA interference response.1

Usage and Biology

Argonaute 2 gene belongs to the argonaute gene family, which encodes for four characteristic domains: N- terminal, PAZ, Mid and a C-terminal PIWI domain. 2

The PAZ domain is named after proteins PIWI, AGO, and Zwille. It binding with the 3' end of siRNA and miRNA due to recognizes the sequence independent manner. The miRNA binds to mRNAs in the partially-complementary sites and reduces its stability and expression levels. 3

The C-terminal PIWI domain is named after Drosophila PIWI protein. It participates in the cleavage activity of his target. 4

Argonaute proteins associate with small RNAs that guide mRNA degradation, translational repression, or a combination of both. The high sequence specificity of Argonaute 2 gene in RNA interference phenomenon in the protein may make it become a suitable treatment for the diseases with elevated expression level of specific gene such as pancreatic cancer. 5

Sequence and Features

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    INCOMPATIBLE WITH RFC[12]
    Illegal NheI site found at 24
  • 21
    INCOMPATIBLE WITH RFC[21]
    Illegal BamHI site found at 1170
    Illegal XhoI site found at 2080
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal NgoMIV site found at 33
    Illegal AgeI site found at 1868
  • 1000
    INCOMPATIBLE WITH RFC[1000]
    Illegal SapI.rc site found at 730


Reference

[1] Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, Tuschl T.(2004 Jul). "Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs". Mol Cell. 23;15(2):185-97. PMID: 15260970 DOI: 10.1016/j.molcel.2004.07.007

[2] Hutvagner G, Simard MJ. (2008). "Argonaute proteins: key players in RNA silencing". Nature Reviews Molecular Cell Biology. 9 (1): 22–32. DOI: 10.1038/nrm2321

[3] Tang G. (Feb 2005). "siRNA and miRNA: an insight into RISCs.". Trends in Biochemical Sciences. 30 (2): 106–14. PMID 15691656. DOI: 10.1016/j.tibs.2004.12.007.

[4] Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, Tuschl T. (Jul 2004). "Human Argonaute2 Mediates RNA Cleavage Targeted by miRNAs and siRNAs". Molecular Cell. 15 (2): 185–197. PMID 15260970. DOI: 10.1016/j.molcel.2004.07.007.

[5] Ronemus M, Vaughn MW, Martienssen RA. (2006 Jul). "MicroRNA-targeted and small interfering RNA-mediated mRNA degradation is regulated by argonaute, dicer, and RNA-dependent RNA polymerase in Arabidopsis". Plant Cell. 18(7):1559-74. Epub 2006 Jun 23. PMID: 16798886 PMCID: PMC1488920 DOI: 10.1105/tpc.106.042127